A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

NCT00210340 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of accrual

Conditions

Lymphoma, B Cell

Interventions

DRUG: intrathecal rituximab

Sponsor

International Extranodal Lymphoma Study Group (IELSG)